UTI Inc has recorded consolidated operating losses and net losses for four consecutive years from 2022 through 2025. Revenue fell sharply from about KRW 36.4 billion in 2022 to KRW 19.4 billion in 2023, then edged up modestly to KRW 18.6 billion in 2024 and KRW 20.0 billion in 2025.
Even so, the operating loss kept widening through the revenue recovery, growing from about KRW 4.6 billion in 2022 to KRW 19.7 billion in 2023, KRW 32.2 billion in 2024, and KRW 48.3 billion in 2025, while the operating margin deteriorated from -12.7% in 2022 to -241.9% in 2025.
Net loss attributable to owners fluctuated between roughly KRW 12.0 billion (2022), KRW 29.5 billion (2023), KRW 22.7 billion (2024), and KRW 37.4 billion (2025).
On a quarterly basis, operating losses exceeded KRW 10 billion in every quarter from 2025Q3 (-KRW 13.3bn) through 2025Q4 (-KRW 15.7bn), 2026Q1 (-KRW 13.2bn), and 2026Q2 (-KRW 15.9bn), keeping the loss trend intact.
However, net income attributable to owners showed much larger quarter-to-quarter swings: the net loss narrowed sharply to about KRW 1.0 billion in 2025Q4 from KRW 15.9 billion in the prior quarter, and then flipped to a net profit of roughly KRW 13.9 billion in 2026Q2 even as the operating loss widened in the same quarter.
This large gap between operating and net results points to the likely influence of non-operating items, making it difficult to conclude that core profitability has genuinely recovered.
On the cash-flow side, operating cash flow swung from about +KRW 3.2 billion in 2022 to -KRW 8.4 billion in 2023, -KRW 31.3 billion in 2024, and -KRW 35.2 billion in 2025, with the cash burn accelerating.
The balance sheet also weakened, as the debt ratio spiked to 485.7% in 2023, eased to 115.5% in 2024, and rose again to 227.4% in 2025.